AzTrials
AzTrials

Type 2 DiabetesHAPPYNCT05949957

Harnessing Human Potential and Improving Health Span in Women and Their Children

A study testing LvL UP App, HAPPY App and Oura Ring And Oura App in people with Type 2 Diabetes and Healthy Lifestyle Behaviors, run by Institute for Human Development and Potential (IHDP), Singapore at 1 site in Singapore.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Women with Gestational Diabetes Mellitus (GDM) are 12-times more likely to develop Type 2 Diabetes (T2D) 4-6 years after delivery than women without GDM. There has been evidence that lifestyle modifications such as physical activity (PA), dietary intake, sleep, and stress management can prevent or delay type 2… Read more about this study

Who is it for?
Ages 21 to 45 years, women onlyHealthy volunteers can take part
What is being tested?
LvL UP App, HAPPY App and Oura Ring And Oura App
Could I receive a placebo?
No, everyone receives an active treatment
How many people
400 participants
Where
1 siteSingapore
Study dates
20 Oct 2023to Sep 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 45 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Female, age: 21 - 45 years
  • Had a history of GDM (at least 1 year and not more than 10 years)
  • Chinese, Malay or Indian ethnic groups
  • Body mass index (at least 18.5 kg/m2 and not more than 35 kg/m2)
  • Not planning to conceive in the next one year
  • Not performing exclusive breastfeeding during study period
Show all 11Show fewer
  • Own a smartphone compatible with the study mobile Apps
  • Proficient in English language
  • Plan to stay in Singapore for the next 4 years
  • Willing to comply to study protocol
  • Able to provide a written informed consent

Who cannot join

  • Current or previous diagnosis of diabetes (Type 1 or 2), except GDM
  • Currently pregnant
  • Given birth within the last 12 weeks
  • Severely limited mobility (e.g., wheelchair bound, require long-term walking aid, etc.)
  • Diagnosed with malnutrition or eating disorder
  • Diagnosed with cancers, unstable heart diseases, severe kidney diseases, severe liver diseases
Show all 10Show fewer
  • Diagnosed with severe insomnia, unstable mental conditions, dementia, or cognitive impairment
  • Experienced alcohol or drug abuse
  • Currently having medications known to influence glucose metabolism (e.g. peroral corticosteroids)
  • Currently participating in concurrent clinical trial or lifestyle intervention study

Trial locations and contacts

1 site in 1 country.

Singapore1 site
  • Singapore Institute for Clinical Sciences (SICS)

    Singapore, 117549

Other trials in Singapore

About this study

Official title: Harnessing Human Potential and Improving Health Span in Women and Their Children: a Randomized Controlled Trial and Follow-up (HAPPY STUDY)

Women with Gestational Diabetes Mellitus (GDM) are 12-times more likely to develop Type 2 Diabetes (T2D) 4-6 years after delivery than women without GDM. There has been evidence that lifestyle modifications such as physical activity (PA), dietary intake, sleep, and stress management can prevent or delay type 2 diabetes (T2D). The purpose of this study is to assess the efficacy of a holistic lifestyle digital health intervention with post-GDM women in large community settings in Singapore. The study consists of a 1-year randomized controlled trial (RCT) with 3 years follow-up. Women who are eligible for the study will be randomized to either Group 1 (Intervention) or Group 2 (Control) at baseline. Both groups will be followed in years 2-4. Women from both groups will be provided with an Oura ring for tracking physical activity, sleep, and heart rate variability (a proxy for stress), and the "HAPPY app," which will provide health promotion information about physical activity, diet, sleep, and mental wellbeing, as well as display the information collected (such as body mass index, blood pressure, and OGTT results). The active group will receive the "LVL UP app" a smartphone-based chatbot-delivered intervention, designed to provide personalized recommendations through multiple digital coaching sessions aimed at improving health literacy and practicing healthy lifestyles to prevent Type 2 diabetes and common mental disorders (i.e., anxiety, depression).

Read the detailed description

The overall goal of this study is to reduce the risk of Type 2 diabetes (T2D) and pre-diabetes in Asian women and their children by focusing upon a major high-risk group - women with a history of gestational diabetes (GDM) in Singapore. GDM is diabetes diagnosed for the first-time during pregnancy and has traditionally been considered a benign condition because typically glucose levels return to normal after delivery. Women with pregnancies complicated by GDM often progress to develop T2D later in life.

There is evidence that holistic lifestyle modifications that include strategies to improve dietary intake, physical activity, and mental well-being can prevent or delay the onset of type 2 diabetes. The use of digital health interventions can also assist in the prevention of T2D. However, limited studies have been conducted with Asian populations.

This study aims (1) to identify post-GDM women from large community settings in Singapore and to assess the efficacy of a holistic lifestyle digital intervention (focusing on diet, physical activity, sleep, and mental well-being) on glucose regulation with those identified women.

Secondary objectives are: (a) to examine the potential impacts of the proposed intervention on the health and well-being of subjects' family members (e.g., children); (b) to determine the diabetes risk of the subjects over a 3-year follow-up period; (c) to explore potential economic impacts of the proposed intervention (e.g., healthcare expenditures); (d) to study the importance of gut microbiota and epigenetic factors in relation to changes in glucose metabolism, and (e) to ascertain the safety of the proposed intervention.

The study is a 1-year randomized controlled trial with three years of follow-up. The primary outcomes involved the incidence of Type 2 diabetes confirmed by a 2-hr 75g Oral Glucose Tolerance Test (OGTT) over a 4-year period. Secondary outcomes are (1) incidence of impaired fasting glucose and impaired glucose tolerance; (b) changes in cardiometabolic variables (e.g., body weight, HbA1c, insulin, blood lipids, blood pressures) in the women; (c) changes in women's body composition; (d) changes in women's mental well-being (e.g., defined by BDI-II, STAI, WHO-5, PSS-4); (e) changes in the health and wellbeing of their children, and (f) a composite of major adverse events (MAE) comprising fatal and non-fatal events associated with Type 2 diabetes.

Eligible women will be randomized at baseline to either Group 1 (Intervention) or Group 2 (Control) for 1 year.

Group 1 (Intervention) consists of several virtual coaching sessions about healthy lifestyle delivered by a conversational agent (chatbot) embedded in the LvL UP App within 24 weeks (weeks 2 to 26) to complete three levels of health literacy. Additionally, individuals will receive an Oura ring at baseline (activity-tracking wearable that collects lifestyle data), as well as the HAPPY App (educational content about lifestyle and health outcomes [e.g., body mass index, blood pressure, OGTT results]).

Group 2 (Control) subjects will receive an Oura ring at baseline, and the HAPPY App

Follow-up Period Upon completion of the one-year RCT period, both groups will be followed-up for 3 years. During the follow-up visits, body measurements, OGTT, bio-sampling, and data collection will be conducted.

Both groups will be assessed at baseline, week 26, 1 year visit, 2-year visit (follow-up 1), 3-year visit (follow-up 2), and 4-year visit (follow-up 3)

Being tested
LvL UP App, HAPPY App, Oura Ring And Oura App
Keywords
Type 2 Diabetes, Gestational Diabetes Mellitus, Women, Prevention, Healthy lifestyle, Physical activity, Diet, Sleep, Mental wellbeing, Digital health interventions
Medical subject headings
Diabetes Mellitus, Type 2, Diabetes, Gestational, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LvL UP AppBehavioural

    LvL UP App: A Smartphone-based conversational agent-delivered holistic lifestyle intervention. The intervention group will receive several digital coaching sessions focus on 3 pillars: diet, physical activity, and mental well-being to promote health literacy and promote healthy lifestyles. The app includes practical exercises per pillar (e.g., journaling, slow-breathing exercises, lifehacks).

  • HAPPY AppBehavioural

    HAPPY App: Each subject will use the HAPPY App that aims to:(1) deliver health promotion information (guided by Singapore Health Promotion Board's resources), and (2) display health data collected (e.g., body mass index, blood pressure, OGTT results) that help them monitor own health and prevent T2D.

  • Oura Ring And Oura AppBehavioural

    Oura ring and Oura App: Each subject will receive an Oura ring, i.e., an activity-tracking wearable that collects lifestyle data (physical activity, sleep and heart rate (as a proxy for stress) that will be synced with Oura App

Study groups in NCT05949957
Study groupRoleWhat they receive
Intervention groupExperimentalLvL UP App (Smarphone-based conversational agent-delivered holistic lifestyle intervention for the prevention of type 2 diabetes, and common mental disorders [anxiety, depression]). HAPPY App (Health promotion information, and display health data collected) Oura ring and Oura App (activity-tracking wearable that collects lifestyle data [physical activity, sleep and heart rate]).
Receives: Behavioral: LvL UP App; Behavioral: HAPPY App; Behavioral: Oura Ring And Oura App
Control groupActive comparatorHAPPY App (Health promotion information, and display health data collected) Oura ring and Oura App (activity-tracking wearable that collects lifestyle data [physical activity, sleep and heart rate]).
Receives: Behavioral: HAPPY App; Behavioral: Oura Ring And Oura App

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Glucose Tolerance Changes

    2-hr 75g Oral Glucose Tolerance Test (OGTT)

    Measured: Changes in glucose over four years, including: Baseline, Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)

Secondary outcomes (13)
  1. Anthropometric Measurements

    Participants will be measured for their height in feet and weight in kilograms. Weight and height will be combined to report BMI in kg/m^2.

    Measured: Baseline, Week 26/27 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)

  2. Blood pressure (BP)

    Blood pressure will be measured using an automated blood pressure monitor.

    Measured: Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)

  3. Biosample Collection (Fasting blood)

    Fasting blood draw will be analyzed for HbA1c \& fasting blood glucose

    Measured: Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)

  4. Biosample Collection (Saliva)

    Saliva collected using Salivette® kit (cortisol)

    Measured: Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)

  5. Biosample Collection (Buccal swab)

    Buccal swab collected using Isohelix kit (DNA profiling)

    Measured: Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)

  6. Biosample Collection (Stool)

    Stool collected via OMNIgene®•GUT OM-200 (Gut microbiota)

    Measured: Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)

  7. Bioelectrical Impedance Analysis (BIA)

    BIA is a non-invasive technology that can accurately measure a person's total body water, extracellular and intracellular fluid volumes.

    Measured: Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)

  8. Depression

    Beck Depression Inventory II (BDI-II)

    Measured: Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)

  9. Anxiety

    The State-Trait Anxiety Inventory (STAI)

    Measured: Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)

  10. Health Status

    The Short Form (36) Health Survey (SF-36)

    Measured: Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)

  11. Sleep

    PSQI: The Pittsburgh Sleep Quality Index (PSQI

    Measured: Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)

  12. Lifestyle

    e-Diary (Qualtrics survey system) self-report lifestyle

    Measured: Baseline, Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)

  13. Social-emotional development (Children)

    ASQ:-3: Ages and stages questionnaire: social-emotional development screening tool is used to assess children's (for age 2 month - 60 months) self-regulation, communication, autonomy, compliance, adaptive functioning, affect, and interaction with people.

    Measured: Baseline, Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jul 2023
  2. Study start20 Oct 2023
  3. Primary completionSep 2026 (estimated)
  4. Study completionSep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
A parallel 2-arm, single-Centre Randomized Control Trial based on 1:1 allocation ratio. Eligible women will be randomized at baseline to either Group 1 (Intervention) or Group 2 (Control). Participants will receive the assigned intervention from baseline to 1 year, followed by 3 years follow-up period.
Masking
None (open label)
Enrolment
400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05949957
Sponsor's protocol ID
2023/00178
Other IDs
2023/00178, 2023
Acronym
HAPPY
Status last verified
Sep 2026
First submitted
8 Jun 2023
Last updated
15 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Salamanca-Sanabria A, Liew SJ, Mair J, De Iorio M, Ling YDY, Tint MT, Wei YT, Lim K, Ong D, Chooi YC, Tay V, Eriksson JG. A holistic lifestyle mobile health intervention for the prevention of type 2 diabetes and common mental disorders in Asian women with a history of gestational diabetes: a randomised control trial with 3-year follow-up protocol. Trials. 2024 Jul 3;25(1):443. doi: 10.1186/s13063-024-08247-x.

    PubMed 38961430

Questions about this trial

What is this clinical trial studying?

A study testing LvL UP App, HAPPY App and Oura Ring And Oura App in people with Type 2 Diabetes and Healthy Lifestyle Behaviors, run by Institute for Human Development and Potential (IHDP), Singapore at 1 site in Singapore.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 15 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Glucose Tolerance Changes (time frame: Changes in glucose over four years, including: Baseline, Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05949957, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in